Abstract:Introduction: Gefitinib (Iressa, ZD 1839, AstraZeneca) blocks the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and inhibits proliferation of several human cancer cell types including breast cancer. Phase II clinical trials with gefitinib monotherapy showed an objective response of 9 to 19% in non-small-cell lung cancer patients and less than 10% for breast cancer, and phase III results have indicated no benefit of gefitinib in combination with chemotherapy over chemotherapy alone. In order to improve the antineoplastic activity of gefitinib, we investigated the effects of blocking the signalling of the insulin-like growth factor 1 receptor (IGF-1R), a tyrosine kinase with a crucial role in malignancy that is coexpressed with EGFR in most human primary breast carcinomas. Methods: AG1024 (an inhibitor of IGF-1R) was used with gefitinib for treatment of MDA468, MDA231, SK-BR-3, and MCF-7 breast cancer lines, which express similar levels of IGF-1R but varying levels of EGFR. Proliferation assays, apoptosis induction studies, and Western blot analyses were conducted with cells treated with AG1024 and gefitinib as single agents and in combination. Results: Gefitinib and AG1024 reduced proliferation in all lines when used as single agents, and when used in combination revealed an additive-to-synergistic effect on cell growth inhibition. Flow cytometry measurements of cells stained with annexin V-propidium iodide and cells stained for caspase-3 activation indicated that adding an IGF-1R-targeting strategy to gefitinib results in higher levels of apoptosis than are achieved with gefitinib alone. Gefitinib either reduced or completely inhibited p42/p44 Erk kinase phosphorylation, depending on the cell line, while Akt phosphorylation was reduced by a combination of the two agents. Overexpression of IGF-1R in SK-BR-3 cells was sufficient to cause a marked enhancement in gefitinib resistance. Conclusion: These results indicate that IGF-1R signaling reduces the antiproliferative effects of gefitinib in several breast cancer cell lines, and that the addition of an anti-IGF-1R strategy to gefitinib treatment may be more effective than a single-agent approach.

Pharmacological interplay between breast cancer resistance protein and gefitinib in epidermal growth factor receptor signaling

Gefitinib-Resistance is Related to Bim Expression in Non-Small Cell Lung Cancer Cell Lines

Beta 1 Integrin Mediated Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Lung Cancer Cells

Breast Cancer Resistance Protein-Mediated 5-Fluorouracil Resistance and Its Mechanism

Integrin Β1 Participates in Acquired Resistance to Gefitinib in Non-Small Cell Lung Cancer

The Role of Up-Regulation of Integrin Β1 in Resistance to Gefitinib in Non-Small Cell Lung Cancer

Integrin Β1-Mediated Acquired Gefitinib Resistance in Non-Small Cell Lung Cancer Cells Occurs Via the Phosphoinositide 3-Kinase-dependent Pathway.

Epidermal Growth Factor Receptor Signaling Pathway Involved in Progestin‐resistance of Human Endometrial Carcinoma: in a Mouse Model

The Epidermal Growth Factor Tyrosine Kinase Inhibitor Ag1478 and Erlotinib Reverse Abcg2-Mediated Drug Resistance

Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells

Gefitinib Reverses Chemotherapy Resistance In Gefitinib-Insensitive Multidrug Resistant Cancer Cells Expressing Atp-Binding Cassette Family Protein

The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation

Phosphorylated Insulin-Like Growth Factor 1 Receptor is Implicated in Resistance to the Cytostatic Effect of Gefitinib in Colorectal Cancer Cells

Selective inhibition of TNF-alpha-induced activation of mitogen-activated protein kinases and metastatic activities by gefitinib

The EGFR pathway regulates BCRP expression in NSCLC cells: role of erlotinib

Epidermal growth factor receptor mutation in combination with expression of MIG6 alters gefitinib sensitivity

Rapamycin Antagonizes BCRP-Mediated Drug Resistance Through the PI3K/Akt/mTOR Signaling Pathway in mPRα-Positive Breast Cancer

Mechanistic Regulation of Epidermal Growth Factor and Hormonal Receptors by Kinase Inhibitors and Organofluorines in Breast Cancer Therapy

BYL719 reverses gefitinib-resistance induced by PI3K/AKT activation in non-small cell lung cancer cells

Reversal of ABCB1- and ABCG2-mediated MDR byerlotinib (tarceva, OSI-774)

Selective Reversal of BCRP-mediated MDR by VEGFR-2 Inhibitor ZM323881